Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Indivior in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $21.85.
Current Consensus is
N/A
The current consensus among 0 contributing investment analysts is to n/a stock in Indivior. This rating has held steady since September 2023, when it changed from a Buy consensus rating.
Indivior PLC is a holding company, which engages in the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence. Its products include Suboxone Film, Suboxone Tablet, and Subutex Tablet. It operates through the following geographical segments: United States, Rest of World, and United Kingdom. The company was founded on September 26, 2014 and is headquartered in Slough, the United Kingdom.
Read More